CNine Bioscolutions, a US-based biomedical spinout from University of Alabama at Birmingham (UAB), has secured $2m in a seed round backed by assorted angel investors, according to the Birmingham Business Journal. CNine is developing a test that can determine whether a patient’s meningitis is caused by bacterial or viral infections. Bacterial meningitis is generally much more serious than viral meningitis and requires immediate intervention. Current tests produce 10% to 30% false positives and lab tests often require hospital visits, making…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?